Table 2.
Final Tuberculosis Treatment Outcome Compared Between Human Immunodeficiency Virus (HIV)–Infected and HIV-Uninfected Multidrug-Resistant Tuberculosis Participants
| Multidrug-Resistant Tuberculosis Treatment Outcome | All Patients (n = 191a) (%) | HIV Infected (n = 138) (%) | HIV Uninfected (n = 53) (%) |
|---|---|---|---|
| Cure | 130b (68.1) | 90 (65.2) | 40 (75.5) |
| Treatment completion | 10 (5.2) | 7 (5.1) | 3 (5.7) |
| Treatment failure | 6 (3.1) | 5 (3.6) | 1 (1.9) |
| Default | 23 (12.0) | 17 (12.3) | 6 (11.3) |
| Died | 22 (11.5) | 19 (13.8) | 3 (5.7) |
Treatment outcomes did not differ significantly between HIV-infected and HIV-uninfected participants (P= .50).
Abbreviation: HIV, human immunodeficiency virus.
aExcludes 13 participants who withdrew from study (10 HIV positive and 3 HIV negative) and 2 participants who moved out of the province during the study and for whom final treatment outcomes were not available.
bTwo patients died after cure and discontinuation of multidrug-resistant tuberculosis treatment.
P = .50 for omnibus χ2 comparison between HIV-infected and HIV-uninfected participants.